세계의 뇌종양 진단 시장 규모, 점유율, 동향 분석 : 제품별, 기술별, 암 종류별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Brain Cancer Diagnostics Market Summary

The Brain cancer diagnostics market size was valued at USD 1.61 billion in 2024 and is expected to reach USD 3.06 billion by 2033, growing at a CAGR of 7.60% from 2025 to 2033. The market growth is driven by the rising global incidence of primary and metastatic brain tumors, coupled with the need for early and accurate detection to guide complex treatment decisions.

Growing adoption of advanced imaging modalities (MRI, PET-MRI), integration of molecular profiling into WHO and NCCN guidelines, and the increasing role of AI-enabled platforms are fueling market growth. In addition, expanding reimbursement for DNA methylation profiling and heightened patient advocacy initiatives are accelerating access, standardization, and demand for innovative diagnostic solutions.

The global brain cancer diagnostics industry represents a high-value, high-need opportunity at the intersection of oncology and advanced diagnostics. Although brain cancers account for just ~2% of all cancers, they rank among the most burdensome malignancies worldwide, driving the fourth highest number of years of life lost across cancers. Treatment costs are exceptionally high, and patients typically undergo lifelong surveillance and follow-up scans. Importantly, until recently, brain tumors were the leading cause of cancer-related death among pediatric and young adult patients, underscoring the unmet medical need.

From a market perspective, this unique disease burden translates into sustained demand for diagnostics. The clinical reality is that therapeutic innovation in brain tumors has lagged behind other cancers; as a result, patient management is disproportionately dependent on accurate, repeated, and advanced diagnostics.

Global Brain Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the brain cancer diagnostics market report based on cancer type, product, technique, end use, and region:

• Technique Outlook (Revenue, USD Million, 2021 - 2033)
• Imaging
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT) Scan
  • PET
  • Single-Photon Emission Computed Tomography (SPECT) Scan
• Tissue Sampling / Biopsy
• Molecular Diagnostics
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments & Systems
• Reagents & Consumables
• Software & AI Solutions
• Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
• Gliomas
• Meningiomas
• Pituitary Tumors
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Oncology Treatment Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Market Definitions
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Cancer Type and Product Snapshot
• 2.3. Technique and End Use Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Business Environment Analysis
  • 3.4.1. PESTLE Analysis
  • 3.4.2. Porter's Five Forces Analysis
• 3.5. COVID-19 Impact Analysis

Chapter 4. Technique Business Analysis

• 4.1. Brain Cancer Diagnostics Market: Technique Movement Analysis, 2024 & 2033
• 4.2. Imaging
  • 4.2.1. Imaging Market, 2021 - 2033 (USD Million)
  • 4.2.2. MRI
    • 4.2.2.1. MRI market, 2021 - 2033 (USD million)
  • 4.2.3. Computed Tomography (CT) Scan
    • 4.2.3.1. Computed Tomography (CT) Scan market, 2021 - 2033 (USD million)
  • 4.2.4. PET
    • 4.2.4.1. PET market, 2021 - 2033 (USD million)
  • 4.2.5. Single-Photon Emission Computed Tomography (SPECT) Scan
    • 4.2.5.1. Single-Photon Emission Computed Tomography (SPECT) Scan market, 2021 - 2033 (USD million)
• 4.3. Tissue Sampling / Biopsy
  • 4.3.1. Tissue Sampling / Biopsy Market, 2021 - 2033 (USD Million)
• 4.4. Molecular Diagnostics
  • 4.4.1. Molecular Diagnostics Market, 2021 - 2033 (USD Million)
• 4.5. Others
  • 4.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Product Business Analysis

• 5.1. Brain Cancer Diagnostics Market: Product Movement Analysis, 2024 & 2033
• 5.2. Instruments & Systems
  • 5.2.1. Instruments & Systems Market, 2021 - 2033 (USD Million)
• 5.3. Reagents & Consumables
  • 5.3.1. Reagents & Consumables market, 2021 - 2033 (USD million)
• 5.4. Software & AI Solutions
  • 5.4.1. Software & AI Solutions market, 2021 - 2033 (USD million)

Chapter 6. Cancer Type Business Analysis

• 6.1. Brain Cancer Diagnostics Market: Cancer Type Movement Analysis, 2024 & 2033
• 6.2. Gliomas
  • 6.2.1. Gliomas Market, 2021 - 2033 (USD Million)
• 6.3. Meningiomas
  • 6.3.1. Meningiomas market, 2021 - 2033 (USD million)
• 6.4. Pituitary Tumors
  • 6.4.1. Pituitary Tumors market, 2021 - 2033 (USD million)
• 6.5. Others
  • 6.5.1. Others market, 2021 - 2033 (USD million)

Chapter 7. End Use Business Analysis

• 7.1. Brain Cancer Diagnostics Market: End Use Movement Analysis, 2024 & 2033
• 7.2. Hospitals
  • 7.2.1. Hospitals Market, 2021 - 2033 (USD Million)
• 7.3. Oncology Treatment Centers
  • 7.3.1. Oncology Treatment Centers Market, 2021 - 2033 (USD Million)
• 7.4. Others
  • 7.4.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Regional Market Snapshot
• 8.2. North America
  • 8.2.1. North America Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.2.2. Key Country Dynamics
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Competitive Scenario
  • 8.2.3. Canada
    • 8.2.3.1. Canada Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.3.2. Key Country Dynamics
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Competitive Scenario
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.4.2. Key Country Dynamics
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Competitive Scenario
• 8.3. Europe
  • 8.3.1. Europe Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.3.2. Germany
    • 8.3.2.1. Germany Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.2.2. Key Country Dynamics
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Competitive Scenario
  • 8.3.3. UK
    • 8.3.3.1. UK Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.3.2. Key Country Dynamics
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Competitive Scenario
  • 8.3.4. France
    • 8.3.4.1. France Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.4.2. Key Country Dynamics
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Competitive Scenario
  • 8.3.5. Italy
    • 8.3.5.1. Italy Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.5.2. Key Country Dynamics
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Competitive Scenario
  • 8.3.6. Spain
    • 8.3.6.1. Spain Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.6.2. Key Country Dynamics
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Competitive Scenario
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.7.2. Key Country Dynamics
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Competitive Scenario
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.8.2. Key Country Dynamics
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Competitive Scenario
  • 8.3.9. Norway
    • 8.3.9.1. Norway Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.9.2. Key Country Dynamics
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Competitive Scenario
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Japan Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.2.2. Key Country Dynamics
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Competitive Scenario
  • 8.4.3. China
    • 8.4.3.1. China Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.3.2. Key Country Dynamics
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Competitive Scenario
  • 8.4.4. India
    • 8.4.4.1. India Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.4.2. Key Country Dynamics
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Competitive Scenario
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.5.2. Key Country Dynamics
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Competitive Scenario
  • 8.4.6. Australia
    • 8.4.6.1. Australia Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.6.2. Key Country Dynamics
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Competitive Scenario
  • 8.4.7. Thailand
    • 8.4.7.1. Thailand Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.7.2. Key Country Dynamics
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Competitive Scenario
• 8.5. Latin America
  • 8.5.1. Latin America Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.5.2. Key Country Dynamics
  • 8.5.3. Regulatory Framework
  • 8.5.4. Competitive Scenario
  • 8.5.5. Brazil
    • 8.5.5.1. Brazil Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.5.2. Key Country Dynamics
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Competitive Scenario
  • 8.5.6. Argentina
    • 8.5.6.1. Argentina Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.6.2. Key Country Dynamics
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Competitive Scenario
• 8.6. MEA
  • 8.6.1. MEA Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.2.2. Key Country Dynamics
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Competitive Scenario
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Saudi Arabia Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.3.2. Key Country Dynamics
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Competitive Scenario
  • 8.6.4. UAE
    • 8.6.4.1. UAE Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.4.2. Key Country Dynamics
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Competitive Scenario
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait Brain Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.5.2. Key Country Dynamics
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Competitive Scenario

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. Acquisition
  • 9.2.2. Collaborations
  • 9.2.3. New Platform Launches
  • 9.2.4. Others
• 9.3. Company Profiles/Listing
  • 9.3.1. Hologic Inc.
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Platform Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. GE Healthcare
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Platform Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Siemens Healthineers
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Platform Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Philips Healthcare
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Platform Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Thermo Fisher Scientific
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Platform Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Illumina, Inc.
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Platform Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Agilent Technologies
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Platform Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Bio-Rad Laboratories
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Platform Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Abbott Laboratories
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Platform Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. F. Hoffmann-La Roche Ltd.
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Platform Benchmarking
    • 9.3.10.4. Strategic Initiatives